REFERENCES
  1. International Drug Monitoring: The Role of National Centres (WHO Technical Report Series No. 498). Geneva: World Health Organization, 1972.
  2. Lee A, Thomas SHL. Adverse drug reactions In: Walker R and Edward C. Clinical pharmacy and Therapeutics. 3rd edition Churchill Livingstone 2003 33-46.
  3. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study.Br Med J 2000; 320: 1036.
  4. Wasserfallen J, Livio F, Buclin T, Tillet L, Yersin B, Biollaz J. Rate, type and cost of adverse drug reactions in emergency department admissions. Eur J Inter Med 2001; 12: 442–7.
  5. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalised patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301–6.
  6. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalised patients. Ann Pharmacother 2000; 34: 1373–9.
  7. lassen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. JAMA 1997; 277(4): 301-6.
  8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
  9. Pourseyed S, Fattahi F, Pourpak Z, Gholami K, Shariatpanahi SS, Moin A, Kazemnejad A, Moin M. Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiol Drug Saf 2008 Dec 19 (Epub ahead of print).
  10. Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother. 1999; 33(2):236-40.
  11. Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J ClinPharmacol 2008; 65(2): 210-6.
  12. Al-Malaq HM, Al-Aqeel SA, Al-Sultan MS. Adverse drug reactions related hospitalization identified by discharge ICD-9 codes in a univeristy hospital in Riyadh. Saudi Med J. 2008 (8):1145-50.
  13. Jha N, Bajracharya O, Namgyal T. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. Kathmandu Univ Med J (KUMJ), 2007 Oct-Dec; 5(4):504-10.
  14. Olsson S. The need for pharmacovigilance In: Gupta SK. Pharmacology and therapeutics in the new millennium. Narosa publishing house, New Delhi 2001 502-8.
  15. WHO. Safety of medicines: A guide to detecting and reporting adverse drug reactions. World Health Organization, Geneva, 2002.
  16. Rawlins M. D.. Clinical pharmacology. Adverse reactions to drugs. British medical journal (Clinical research ed.), 282, 974-976 1981
  17. Hallit S, Hajj A, Shuhaiber P et al. Medication safety knowledge, attitude, and practice among hospital pharmacists in Lebanon. Journal of Evaluation in Clinical Practice 2019.25(2):323-39. https://doi.org/10.1111/jep.13082
  18. JSI Research & Training Institute, Inc. The KAP survey model, 2011. https://www.spring-nutrition.org/publications/tool-summaries/kap-survey-model-knowledge-attitudes-and-practices
  19. Aline Hajj, Souheil Hallit, Elsy Ramia, Pascale Salameh & on behalf of the Order of Pharmacists Scientific Committee – Medication Safety Subcommittee (2017): Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon, Current Medical Research and Opinion, DOI: 10.1080/03007995.2017.1361916.
  20. Kalaiselvan V, Prasad T, Singh A. Current Status of Adverse Drug Reactions Monitoring Centres under Pharmacovigilance Programme of India. Indian J Pharm Prac. 2014;7:19-22.
  21. Murdaugh LB. Competence Assessment Tools for Health-System Pharmacies. (4th ed), American Society of Health System Pharmacists, USA: 2007:439-40.
  22. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. Ther Clin Risk Manag. 2005;1(3):181-8.
  23. Parthasarathy G, Karin NH, Milap N. Clinic Pharmacy Book: Essential Concepts and Skills. Hyderabad: Universities Press; 2008:43-53.
  24. Bhagavathula AS, Elnour AA, Jamshed SQ. Health Professionals’ Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis. 2016 Jan;11(3):e0152221.
  25. Ravinandan AP,Achutha V, Vikram K Ramani, Santosh Uttangi, Sushil Kumar L. Study Of Knowledge, Attitude, And Practice Of Pharmacist Towards Adverse Drug Reaction Reporting In Davangere City. Asian J Pharm Clin Res, Vol 8, Issue 3, 2015, 262-265
  26. Yu XM, Lee E,Koo BS, Jeong KH, Choi KH, Kang LK, et al. Predictive Factors of Spontaneous Reporting of Adverse Drug Reactions among Community Pharmacists. PloS one. 2016;11(5):e0155517.
  27. Qassim S, Metwaly Z, Shamsain M, Al Hariri Y. Reporting adverse drug reactions: Evaluation of knowledge, attitude and practice among community pharmacists in UAE. IOSR J Pharm 2014;4(4):17-23.
  28. Jose J, Jimmy B, Al-Ghailani AS, Al Majali MA. A cross sectional pilot study on assessing the knowledge, attitude and behavior of community pharmacists to adverse drug reaction related aspects in the Sultanate of Oman. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2014;22(2):163-9
  29. Khalili H, Mohebbi N, Hendoiee N, Keshtkar AA, Dashti-Khavidaki S. Improvement of knowledge, attitude and perception of healthcare workers about ADR, a pre- and post-clinical pharmacists’ interventional study. BMJ open. 2012;2:e000367.
  30. Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiology and drug safety. 2010;19(3):217-22.
  31. Bawazir OA, Alsuwayt B, Alqahtani W, Al-Dhafiri A, Al-Shamrani M. Knowledge, attitude and practice of pediatricians and pharmacists in Riyadh City toward the use of sugar free medications. The journal of contemporary dental practice. 2014;15(6):755-60.
  32. Ravinder K. Sah, Rakhamaji D. Chandane, Krishna, Sachin Manocha, Ajita Kapur. Knowledge, attitude and practice of pharmacovigilance among community pharmacists in Delhi, India. International Journal of Basic & Clinical Pharmacology | March 2017 | Vol 6 | Issue 3
  33. Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Influence of attitudes on pharmacists’ intention to report serious adverse drug events to the Food and Drug Administration. British journal of clinical pharmacology. 2011;72(1):143-52.
  34. Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug safety. 2000;23(2):165-72.
  35. Gavaza P, Brown CM, Lawson KA, Rascati KL, Steinhardt M, Wilson JP. Pharmacist reporting of serious adverse drug events to the Food and Drug Administration. Journal of the American Pharmacists Association : JAPhA. 2012;52(5):e109-12.
  36. Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Texas pharmacists’ knowledge of reporting serious adverse drug events to the Food and Drug Administration. Journal of the American Pharmacists Association : JAPhA. 2011,51(3);397-403.
  37. Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernandez-Diaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug safety. 2007;30(11):1073-82.
  38. Ribeiro-Vaz I, Herdeiro MT, Polonia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Revista de saude publica. 2011;45(1):129-35.
  39. Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug safety. 2008;31(4):335-44.
  40. Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Jama. 2006;296(9):1086-93.
  41. Salim M. The Current Perspective of Community Pharmacists towards Pharmacovigilance. J Pharmacovigil. 2015;3:180.
  42. Suyagh M, Farah D, Farha RA. Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharmaceutical Journal. 2015;23:147-53.
  43. Grootheest AC, Mes K, Van den berg LT, et al. Attitudes of community pharmacists in the Netherlands towards adverse drug reaction reporting. Int J Pharm Pract 2002;10(4):267-72.
  44. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse
drug reactions: A review of published literature and international experience. Br J Clin Pharmacol 2007;63(2):148-56.
  1. van Hunsel F, Passier A, van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: The broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol 2009;67(5):558‑64.
  2. Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res 2013;4(4):204-10.